Ann Byrne

1.7k total citations
9 papers, 316 citations indexed

About

Ann Byrne is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ann Byrne has authored 9 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ann Byrne's work include Medical Imaging Techniques and Applications (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Ann Byrne is often cited by papers focused on Medical Imaging Techniques and Applications (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Ann Byrne collaborates with scholars based in Australia, United Kingdom and Belgium. Ann Byrne's co-authors include Sneha Sant, Balaji Virassamy, Peter Savas, Stephen J. Luen, Sherene Loi, Paul J. Neeson, Ran Li, Laura K. Mackay, Paul A. Beavis and F. J. Dudley and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Ann Byrne

9 papers receiving 309 citations

Peers

Ann Byrne

ONCOL

IMMUN

PRM

SURGE

Marc Lucas Ooft Netherlands

Haiqing Ni China

Emanuela Romagnoli Italy

Yanmei Gu China

Minae An South Korea

Loïc Steiner Sweden

Hordur M. Kolbeinsson United States

Ryan C Jacobs United States

Rasmus Peuliche Vogelsang Denmark

Marc Lucas Ooft Netherlands

Ann Byrne

295 ×1.7

ONCOL

186 ×1.4

IMMUN

62 ×0.7

PRM

102 ×1.4

45 ×1.0

SURGE

Citations per year, relative to Ann Byrne Ann Byrne (= 1×) peers Marc Lucas Ooft

Countries citing papers authored by Ann Byrne

Since Specialization

Citations

This map shows the geographic impact of Ann Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Byrne more than expected).

Fields of papers citing papers by Ann Byrne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Byrne. The network helps show where Ann Byrne may publish in the future.

Co-authorship network of co-authors of Ann Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Byrne. A scholar is included among the top collaborators of Ann Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Byrne. Ann Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Teo, Zhi L., Mark J. O’Connor, Christopher Mintoff, et al.. (2023). Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. npj Breast Cancer. 9(1). 68–68. 14 indexed citations

Li, Ran, Sneha Sant, Franco Caramia, et al.. (2023). Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer. JNCI Journal of the National Cancer Institute. 115(7). 805–814. 9 indexed citations

Li, Ran, Sneha Sant, Franco Caramia, et al.. (2021). Abstract PS10-04: Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2+ murine model. Cancer Research. 81(4_Supplement). PS10–4. 3 indexed citations

Byrne, Ann, Peter Savas, Sneha Sant, et al.. (2020). Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology. 17(6). 341–348. 211 indexed citations

Ghanem, Mazen A., Rebecca Herbertson, Salvatore U. Berlangieri, et al.. (2009). Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma. Molecular Imaging and Biology. 11(6). 473–479. 24 indexed citations

Poon, Aurora, Salvatore U. Berlangieri, Ann Byrne, et al.. (2007). Role of Low-dose, Noncontrast Computed Tomography from Integrated Positron Emission Tomography/Computed Tomography in Evaluating Incidental 2-Deoxy-2-[F-18]fluoro-d-glucose-avid Colon Lesions. Molecular Imaging and Biology. 10(1). 48–53. 15 indexed citations

Berlangieri, Salvatore U., Aurora Poon, Paul Mitchell, et al.. (2007). Prevalence of occult metastatic disease in patients undergoing ¹⁸F‐FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. Internal Medicine Journal. 37(11). 753–759. 3 indexed citations

Scott, Andrew M., et al.. (2007). ¹⁸F-FDG PET changes management and improves prognostic stratification in patients with colorectal cancer: results of a prospective, multi-centre study. Journal of Clinical Oncology. 25(18_suppl). 4025–4025. 2 indexed citations

McLean, A. J., Paul M. Harrison, Lisa L. Ioannides‐Demos, et al.. (1985). THE CHOICE OF ULCER HEALING AGENT INFLUENCES DUODENAL ULCER RELAPSE RATE AND LONG‐TERM CLINICAL OUTCOME. Australian and New Zealand Journal of Medicine. 15(3). 367–374. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact